Profil bibliographique

Alexis B. Cortot

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

7Publications signalées

0Citations signalées

7Affiliations récentes

Institutions déclarées

Centre National de la Recherche Scientifique Inserm Université de Lille Institut Pasteur de Lille Centre Hospitalier Universitaire de Lille Lille’s Cardiology Hospital CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers

Domaines associés

Lung Cancer Research StudiesLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCancer Immunotherapy and BiomarkersNeuroendocrine Tumor Research Advances

Publications récentes

2026 conference-abstractOpenAlex

Paclitaxel, carboplatin, and durvalumab in extensive stage small-cell lung cancer (ES-SCLC; IFCT-2203 TAXIO phase II trial): Can we improve the chemotherapy (CT) immunotherapy combination in SCLC?

Denis Lucien MORO SIBILOT, A. Baranzelli, Etienne Giroux‐Leprieur, Karim Amrane et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Five-year overall survival in lung adenocarcinoma: Real-world results from three French nationwide cohorts (2000–2010–2020).

D. Debieuvre, Federico Di Meglio, Le Garff Gwenaëlle, Thomas Laurent et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

IFCT-2401 SPORADIC trial: Integrating cemiplimab to sequential hypofractionated chemoradiotherapy for unfit or elderly patients with unresectable stage III non–small cell lung cancer.

S. Thureau, Judith Raimbourg, N. Pourel, Hubert Curcio et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Phase Ib results from the phase Ib/II study of [ 177 Lu]Lu-DOTA-TATE in combination with standard of care as a first-line treatment for pts with extensive-stage small cell lung cancer.

Stephen V. Liu, Pedro Rocha, K Herrmann, Luis G. Paz-Ares et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

PP01.27: Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) From the VISION Study: ≥3-Year Follow-Up Outcomes

Paul K. Paik, Remi Veillon, Alexis B. Cortot, Roberto Ferrara et autres

0 citationsJournal of Thoracic Oncology

2026 conference-abstractOpenAlex

PP01.23: Safety and Patient-Reported Outcomes with Tepotinib in Patients with METex14 Skipping NSCLC: ≥3-Years Follow-Up of VISION

Paul K. Paik, Roberto Ferrara, Remi Veillon, Xiuning Le et autres

0 citationsJournal of Thoracic Oncology

2026 conference-abstractOpenAlex

PP01.29: Long-Term Outcomes with Tepotinib for Clinically Relevant Subgroups of Patients with MET Exon 14 (METex14) Skipping NSCLC in the VISION Study: A ≥3-Year Follow-Up

Paul K. Paik, Roberto Ferrara, Enriqueta Felip, Egbert F. Smit et autres

0 citationsJournal of Thoracic Oncology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.